Management of Hepatitis C Infection

  • Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 7/24/18 (What's New)

Summary

  • Pibrentasvir is an NS5A inhibitor
  • Pibrentasvir is approved by the FDA and the EMA as part of the coformulation glecaprevir/pibrentasvir for first-line treatment of genotypes 1-6 chronic HCV infection[FDA Glecaprevir Pibrentasvir; EMA Glecaprevir Pibrentasvir]
    • Some treatment-experienced patients are also eligible for treatment with this coformulation, depending on the type of agent previously used and HCV genotype

Action required